These factors include total dose of oxaliplatin, baseline platelet count, M stage, albumin, and natural killer cells, which have demonstrated a good predictive effect on risk for thrombocytopenia in patients with CRC treated with oxaliplatin [11]. This evidence concerns the gene ALB and colorectal carcinoma.